To do this, we pose the following research question: do the risk variants in SNVs of IFNAR1 or IFNAR2 of patients with severe COVID-19 affect the antiviral immune response or lead to poor outcomes compared to noncarriers individuals of risk variants? Here, IFNAR2 is linked to COVID-19.